Basic information
- CAS
82952-64-5- Standard SMILES
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)O- InChIKey
ZCJXQWYMBJYJNB-LRDBBFHQSA-N- Molecular formula
- C25H33N5O10
- Average molar mass
- 563.6 g/mol
- Monoisotopic mass
- 563.22274227
Overview
Trimetrexate Glucuronate can cause developmental toxicity according to state or federal government labeling requirements.
Names & identifiers
- Preferred name
- Trimetrexate Glucuronate
- IUPAC
- 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid
- English name
- Trimetrexate glucuronate
- Molecular formula
- C19H23N5O3.C6H10O7
- Molecular weight
- 563.56
Names & synonyms
TRIMETREXATE GLUCURONATE82952-64-5Trimetrexate D-glucuronateNSC-352122L137U4A79KDTXSID902739682,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline mono-D-glucuronateNSC352122trimetrexate glucuronic acid combinationRefChem:56176DTXCID90196461Trimetrexate (glucuronate)
Show more names
CI 898 dihydrochlorideCI 898 TRIHYDROCHLORIDE5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]quinazoline-2,4-diamine D-glucuronate5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediaminetrihydrochloride
Trimetrexate glucuronate [USAN]CI 898 D-Glucuronic Acid Salt (Trimetrexate D-Glucuronic Acid Salt)2,4-Quinazolinediamine, 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-, mono-D-glucuronate5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acidTrimetrexate glucuronate (USAN)Neutrexin (TN)DRG-0183NSC 352122
Database identifiers
Properties
Computed structural properties
- Topological polar surface area
- 253 Ų
- Hydrogen bond donors
- 8
- Hydrogen bond acceptors
- 15
- Rotatable bonds
- 11
- Heavy atoms
- 40
- Formal charge
- 0
- Complexity
- 648
Experimental & physicochemical properties
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physicochemical properties
- storage temp.
- -20 °C · Store at -20°C
- form
- Solid
- color
- Off-white to light yellow
- NCI Dictionary of Cancer Terms
- trimetrexate glucuronate
- FDA UNII
- 137 U4A79K · L137U4A79K
- NCI Drug Dictionary
- trimetrexate glucuronate
- Proposition 65 List
- Trimetrexate Glucuronate
- Symbol(GHS)
- 8 · GHS08
- Signal word
- Warning
- Hazard statements
- 361 · H361
- Precautionary statements
- 201 · P201-P202-P281-P308+P313-P405-P501
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Hazard information
Regulatory InformationHazard Traits - Developmental Toxicity
Hazard Classes and CategoriesRepr. 2 (100%)
Toxicology
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Trimetrexate glucuronate
Ambiguous-DILI-concern
3
Warnings & precautions
DOI:10.1016/j.drudis.2016.02.015
Safety data
- Signal word
- Warning
- Symbol(GHS)
- GHS08
- Hazard statements
- H361
- Precautionary statements
- P201-P202-P281-P308+P313-P405-P501
Chemistry & industry
Applications
DescriptionTrimetrexate glucuronate is a nonclassical antifolate introduced in the U.S.A. and Canada as second-line therapy for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis in AIDS patients who are refractory or intolerant to co-trimoxazole therapy. Trimetrexate glucuronate is reportedly to be in clinical trials for the treatment of several types of cancer including colorectal, gastric, pancreas, prostate, bladder, lung, breast, head, and neck cancers. It is also in early clinical trials for topical use in treating psoriasis and as an oral drug to treat rheumatoid arthritis. The mechanism of action of trimetrexate glucuronate is via inhibition of the enzyme dihydrofolate reductase which mediates the reduction of dihydrofolate to tetrahydrofolic acid and results in disruption of DNA, RNA and protein synthesis, with consequent cell death. Due to its toxicity to bone marrow and the GI tract, trimetrexate glucuronate must be concurrently administered with leucovorin as a rescue agent.
UsesAntineoplastic.
UsesCI 898 Glucuronate is a dihydrofolate reductase (DHFR) inhibitor.
Upstream & downstream products
Upstream raw materials
Suppliers8 total
武汉易泰科技有限公司上海分公司18930552037 · [email protected]
安耐吉化学&3A（安徽泽升科技有限公司）021-58432009 400-005-6266 · [email protected]
Chongqing jooe co., ltd+86-15223382610 · [email protected]
EMMX Biotechnology LLC888-539-0666 · [email protected]
上海陶术生物科技股份有限公司
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…